Industries

3D Bioprinting and Bioinks

Name: 3D Bioprinting and Bioinks
Creator: Sell to Scientists

3D bioprinting deposits living cells, bioinks, and hydrogels layer by layer to fabricate three-dimensional tissue constructs that recapitulate the architecture and function of native organs far more accurately than flat 2D culture. CELLINK (now BICO), Organovo, Aspect Biosystems, RegenHU, and Advanced Solutions Life Sciences supply extrusion-, inkjet-, laser-assisted, and stereolithography-based bioprinters alongside tailored bioink portfolios—alginate, GelMA, fibrin, decellularized ECM—optimized for printability and cell viability. Researchers procure complete bioprinting workstations, crosslinking modules, integrated incubation chambers, and post-print culture consumables. The pharmaceutical industry increasingly adopts bioprinted liver, cardiac, and kidney models to reduce animal use in ADMET screening, while EU Horizon and NIH funding channels drive academic procurement of multi-material bioprinting systems. Sell to Scientists CLI matches research labs with bioink formulation suppliers, printer validation service providers, and academic bioprinting core facilities worldwide.

Details

Companies: OrganovoCELLINK (BICO)Envision TECAlleviRegenHUAspect BiosystemsAdvanced Solutions Life Sciences
Market Size: $2.0 billion (2024), projected $7.8 billion by 2030 at 25.4% CAGR
Target Researchers: Tissue engineers, regenerative medicine researchers, drug testing scientists, organ-on-chip developers, and biomaterials scientists fabricating living 3D constructs.
Use Cases: Patient-specific tissue models for drug toxicity screeningVascularized tissue constructs for regenerative medicineScaffold-free spheroid and organoid bioprintingBioprinted skin equivalents for cosmetics testingCartilage and bone scaffolds for orthopedic researchCornea and eye tissue models for ophthalmic drug screeningTumor microenvironment models for immuno-oncology